Aktieanalys

Moberg Pharma Q1’23: No surprises and on track - Redeye

Redeye Publicerad: 09 May 2023 08:50

Redeye’s initial comment on the Q1 report was published earlier this morning. There were no sales, as expected. Progress continues as expected and awaits the results of the registration process. We continue to see that Moberg Pharma is on schedule for commercialization. We expect to decrease our valuation slightly c 10% after the report as we push some milestone payments into next year and higher capitalized R&D costs. The effects are minor as most of the company’s value is unrelated to near-term development.

Länk till analysen i sin helhet: https://www.redeye.se/research/904629/moberg-pharma-q123-no-surprises-and-on-track?utm_source=finwire&utm_medium=RSS

Nyheter om Moberg Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!